Human IGF-1 ELISA detection is a widely used immunoassay technique for quantitative measurement of insulin-like growth factor 1 in biological samples, supporting research in growth disorders, endocrine function, and metabolic diseases. This enzyme-linked immunosorbent assay offers high sensitivity, specificity, and reproducibility, making it an essential tool in clinical diagnostics and biomedical research laboratories.
Technical Overview
Insulin-like Growth Factor 1 (IGF-1), also known as somatomedin C, is a 70-amino acid polypeptide hormone with a molecular weight of approximately 7.6 kDa. It is primarily produced by the liver in response to growth hormone (GH) stimulation and plays a crucial role in cell growth, differentiation, and metabolism. Human IGF-1 ELISA detection employs the double-antibody sandwich enzyme-linked immunosorbent assay principle, utilizing specific capture antibodies immobilized on a microplate to bind IGF-1 in patient samples.
The assay typically follows a standard protocol where samples and standards are added to pre-coated wells, followed by the addition of a detection antibody conjugated with horseradish peroxidase (HRP). After incubation and washing steps, a chromogenic substrate such as TMB (3,3',5,5'-tetramethylbenzidine) is added, producing a colorimetric reaction proportional to the IGF-1 concentration. The optical density is measured at 450 nm using a microplate reader, and concentrations are calculated from a standard curve generated with known IGF-1 standards.
An important consideration in IGF-1 measurement is that circulating IGF-1 exists predominantly bound to IGF-binding proteins (IGFBPs), with less than 1% present in the free form. Therefore, most commercial ELISA kits incorporate a pre-treatment step with an acidic buffer or blocking reagent to dissociate IGF-1 from its binding proteins, ensuring accurate total IGF-1 quantification.
Testing Samples
Serum Samples
Serum is the most commonly used sample type for IGF-1 ELISA detection. Collect venous blood using standard venipuncture procedures and allow it to clot for 30 minutes at room temperature before centrifugation at 2000-3000 × g for 10-15 minutes. The separated serum should be clear and free from hemolysis, lipemia, or fibrin particles. Serum samples can be stored at 2-8°C for up to 48 hours or at -20°C/-80°C for long-term storage, avoiding repeated freeze-thaw cycles.
Plasma Samples
Plasma can be collected using anticoagulants such as EDTA or heparin. After collection, gently invert the tube several times to ensure proper mixing with the anticoagulant, then centrifuge at 2000-3000 × g for 15 minutes within 30 minutes of collection. Note that citrate plasma may not be suitable for certain assays. Store plasma samples under the same conditions as serum, with aliquoting recommended to prevent repeated freeze-thaw cycles.
Cell Culture Supernatants
For in vitro studies examining IGF-1 secretion by cultured cells, collect conditioned media and centrifuge at 1000 × g for 5-10 minutes to remove cell debris. The supernatant can be assayed directly or stored at -20°C to -80°C. Depending on the expected IGF-1 concentration, dilution may be necessary to fall within the assay's detection range.
Tissue Homogenates
Tissue samples should be rinsed thoroughly in cold PBS to remove blood contamination, minced into small pieces, and homogenized in an appropriate lysis buffer. Centrifuge the homogenate at 5000 × g for 5-10 minutes at 4°C and collect the supernatant for analysis. Total protein concentration should be determined for normalization purposes.
Testing Items
The Human IGF-1 ELISA kit is designed to quantitatively measure total IGF-1 concentrations in human biological samples. The key testing parameters include:
- Detection range: typically 0.3–100 ng/mL, depending on the specific kit manufacturer
- Sensitivity (minimum detection limit): generally less than 0.1 ng/mL
- Specificity: high specificity for human IGF-1 with negligible cross-reactivity with IGF-2, insulin, and other related growth factors
- Recovery rate: typically 85-115% in standard spiked recovery experiments
- Intra-assay precision: coefficient of variation (CV) typically less than 10%
- Inter-assay precision: coefficient of variation (CV) typically less than 15%
- Standard curve calibration using recombinant human IGF-1 standards with 4-parameter logistic (4PL) fitting
Reference ranges for serum IGF-1 vary significantly with age and sex, as IGF-1 levels peak during puberty and decline with advancing age. Clinical interpretation should always be performed in the context of age-matched and sex-matched normative data provided by the laboratory or kit manufacturer.
Testing Methods
The standard protocol for Human IGF-1 ELISA detection involves the following steps:
- Reagent preparation: Bring all reagents and samples to room temperature (18-25°C) before use. Prepare wash buffer, standard dilutions, and working detection antibody solution according to the manufacturer's instructions.
- Sample pre-treatment: Perform acid-ethanol extraction or use the supplied dissociation reagent to release IGF-1 from IGFBPs, then neutralize the samples before analysis.
- Standard and sample addition: Add 50-100 μL of standards, controls, and pre-treated samples to the appropriate wells of the pre-coated microplate in duplicate or triplicate.
- Incubation: Incubate the plate at 37°C for 60-120 minutes, depending on the kit protocol, to allow binding of IGF-1 to the immobilized capture antibody.
- Washing: Aspirate the well contents and wash 3-5 times with wash buffer (approximately 300-400 μL per well), ensuring complete removal of unbound material.
- Detection antibody addition: Add the HRP-conjugated detection antibody to each well and incubate at 37°C for 30-60 minutes.
- Substrate reaction: After an additional washing step, add TMB substrate solution and incubate in the dark at 37°C for 10-20 minutes until appropriate color development occurs.
- Stop reaction and measurement: Add the stop solution (typically 0.5-2 M sulfuric acid) to terminate the reaction, and read the optical density at 450 nm within 5-15 minutes using a microplate reader.
- Data analysis: Generate a standard curve using 4PL or 5PL regression analysis and calculate sample concentrations, applying appropriate dilution factors.
Strict adherence to incubation times, washing procedures, and temperature conditions is essential for achieving reliable and reproducible results. All samples should be analyzed in duplicate or triplicate to monitor assay precision, and results with CV values exceeding 15% between replicates should be repeated.
Applications
Human IGF-1 ELISA detection serves multiple purposes across clinical diagnostics and biomedical research:
- Growth disorder diagnosis: Evaluation of growth hormone deficiency (GHD), idiopathic short stature, and growth hormone insensitivity syndrome (Laron syndrome)
- Acromegaly and gigantism management: Diagnosis, treatment monitoring, and disease surveillance in patients with GH-secreting pituitary adenomas
- Endocrine research: Investigation of the GH/IGF-1 axis function and its regulation under various physiological and pathological conditions
- Metabolic disease studies: Assessment of IGF-1 levels in diabetes mellitus, obesity, metabolic syndrome, and insulin resistance
- Nutritional status evaluation: Monitoring IGF-1 as a biomarker for protein-energy malnutrition and nutritional recovery
- Chronic liver disease assessment: Evaluation of hepatic synthetic function, as IGF-1 is primarily produced by hepatocytes
- Anti-doping testing: Detection of exogenous GH abuse through IGF-1 and related biomarker monitoring
- Longevity and aging research: Investigation of the relationship between IGF-1 signaling pathways and lifespan, age-related diseases, and frailty
- Oncology research: Study of IGF-1 involvement in tumor cell proliferation, metastasis, and therapeutic response
FAQ
What is the difference between free IGF-1 and total IGF-1 measurement?
Total IGF-1 measurement quantifies both free and bound IGF-1 after dissociating it from IGFBPs during sample pre-treatment. Free IGF-1 measurement does not include the dissociation step and reflects only the biologically active, unbound fraction. Total IGF-1 is the standard clinical measurement, while free IGF-1 assays are primarily used in specialized research settings.
Why is sample pre-treatment necessary for IGF-1 ELISA?
IGF-1 circulates in blood almost entirely bound to high-affinity IGF-binding proteins (IGFBPs), which can interfere with antibody binding in the ELISA. Acidic pre-treatment or specialized dissociation reagents are required to release IGF-1 from these binding proteins, ensuring complete and accurate measurement of total IGF-1.
What factors can affect IGF-1 test results?
Numerous factors influence circulating IGF-1 levels, including age, sex, nutritional status, liver function, renal function, pregnancy, and certain medications (e.g., recombinant GH therapy, oral estrogen, corticosteroids). Diurnal variation is less pronounced for IGF-1 compared to GH, but fasting status, stress, and exercise can still affect results. Proper sample handling and avoiding hemolysis are also critical for accurate measurement.
How should IGF-1 results be interpreted clinically?
IGF-1 results must be interpreted in conjunction with age-specific and sex-specific reference ranges. Elevated IGF-1 levels may suggest acromegaly, gigantism, or pubertal growth spurts, while low levels may indicate GH deficiency, hypopituitarism, malnutrition, or severe liver disease. A single IGF-1 measurement cannot definitively diagnose GH disorders and should be confirmed with additional stimulation or suppression tests, along with clinical and imaging findings.
What quality control measures should be implemented?
Laboratories should include internal quality control samples with known low, medium, and high IGF-1 concentrations in each run to verify assay performance. Regular participation in external quality assessment programs, calibration verification, and lot-to-lot comparison studies are recommended to ensure result comparability and regulatory compliance.